TOULOUSE, France & ANN ARBOR, Mich.--(BUSINESS WIRE)-- Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and metabolic ...
CERo Therapeutics Holdings, Inc. announced that it will present preclinical data for its lead compound, CER-1236, targeting ovarian cancer during the Spring Scientific meeting of the Society for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback